Abstract
Background: The past 3 decades have seen an unprecedented shift toward treatment de-escalation in surgical therapy of breast cancer. Summary: Radical mastectomy has been replaced by breast-conserving and oncoplastic approaches in most patients, and full axillary lymph node dissection by less radical staging procedures, such as sentinel lymph node biopsy and targeted axillary dissection. Further, attempts have been made to spare healthy tissue while increasing the probability of removing the tumor with clear margins, thus improving cosmetic results and minimizing the risk of local recurrence. In this context, modern probe-guided localization techniques have been introduced to guide surgical excision. This progress was accompanied by the development of targeted systemic therapies. At the same time, radiotherapy for breast cancer has undergone significant changes. The use of hypofractionation has decreased the typical length of a treatment course from 5–6 weeks to 1–3 weeks. Partial breast irradiation is now a valid option for de-escalation in patients with low-risk features. Axillary radiotherapy achieves similar recurrence rates and decreases the risk of lymphedema in patients with limited sentinel node involvement. Key Messages: Taken together, these advances are important steps toward individualization of locoregional management strategies. This highlights the importance of interdisciplinary approaches for de-escalation of locoregional therapies.
Journal Section:
Review Article
References
1.
Rutherford CL, Barker S, Romics L. A systematic review of oncoplastic volume replacement breast surgery: oncological safety and cosmetic outcome. Ann R Coll Surg Engl. 2022;104(1):5–17.
2.
Mohamedahmed AYY, Zaman S, Zafar S, Laroiya I, Iqbal J, Tan MLH, et al. Comparison of surgical and oncological outcomes between oncoplastic breast-conserving surgery versus conventional breast-conserving surgery for treatment of breast cancer: a systematic review and meta-analysis of 31 studies. Surg Oncol. 2022;42:101779.
3.
Andre C, Holsti C, Svenner A, Sackey H, Oikonomou I, Appelgren M, et al. Recurrence and survival after standard versus oncoplastic breast-conserving surgery for breast cancer. BJS Open. 2021;5(1):zraa013.
4.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.
5.
Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (alliance). J Clin Oncol. 2023;41(17):3184–93.
6.
Ditsch N, Wöcke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2022. Breast Care. 2022;17(4):403–20.
7.
Kosasih S, Tayeh S, Mokbel K, Kasem A. Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients. Am J Surg. 2020;220(2):385–92.
8.
Ostapenko E, Nixdorf L, Devyatko Y, Exner R, Wimmer K, Fitzal F. Prepectoral versus subpectoral implant-based breast reconstruction: a systemic review and meta-analysis. Ann Surg Oncol. 2023;30(1):126–36.
9.
Schermers B, van Riet YE, Schipper RJ, Vrancken Peeters MJ, Voogd AC, Nieuwenhuijzen GAP, et al. Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer. Br J Surg. 2021;109(1):53–60.
10.
Somasundaram SK, Potter S, Elgammal S, Maxwell AJ, Sami AS, Down SK, et al. Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire. Breast Cancer Res Treat. 2021;185(1):13–20.
11.
Chan BK, Wiseberg-Firtell JA, Jois RHS, Jensen K, Audisio RA. Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database Syst Rev. 2015;2015(12):CD009206.
12.
Banys-Paluchowski M, Kühn T, Masannat Y, Rubio I, de Boniface J, Ditsch N, et al. Localization techniques for non-palpable breast lesions: current status, knowledge gaps, and rationale for the MELODY study (EUBREAST-4/iBRA-NET, NCT 05559411). Cancers. 2023;15(4):1173.
13.
Schwartz GF, Goldberg BB, Rifkin MD, D’Orazio SE. Ultrasonography: an alternative to x-ray-guided needle localization of nonpalpable breast masses. Surgery. 1988;104(5):870–3.
14.
Banys-Paluchowski M, Rubio IT, Karadeniz Cakmak G, Esgueva A, Krawczyk N, Paluchowski P, et al. Intraoperative ultrasound-guided excision of non-palpable and palpable breast cancer: systematic review and meta-analysis. Ultraschall Med. 2022;43(4):367–79.
15.
Athanasiou C, Mallidis E, Tuffaha H. Comparative effectiveness of different localization techniques for non-palpable breast cancer. A systematic review and network meta-analysis. Eur J Surg Oncol. 2022;48(1):53–9.
16.
Davey MG, O’Donnell JPM, Boland MR, Ryan ÉJ, Walsh SR, Kerin MJ, et al. Optimal localization strategies for non-palpable breast cancers -a network meta-analysis of randomized controlled trials. Breast. 2022;62:103–13.
17.
Dave RV, Barrett E, Morgan J, Chandarana M, Elgammal S, Barnes N, et al. Wire- and magnetic-seed-guided localization of impalpable breast lesions: iBRA-NET localisation study. Br J Surg. 2022;109(3):274–82.
18.
Bloomquist EV, Ajkay N, Patil S, Collett AE, Frazier TG, Barrio AV. A randomized prospective comparison of patient-assessed satisfaction and clinical outcomes with radioactive seed localization versus wire localization. Breast J. 2016;22(2):151–7.
19.
Micha AE, Sinnett V, Downey K, Allen S, Bishop B, Hector LR, et al. Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions. Breast Cancer. 2021;28(1):196–205.
20.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
21.
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.
22.
Krug D, Baumann R, Combs SE, Duma MN, Dunst J, Feyer P, et al. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: considerations regarding FAST and FAST-Forward. Strahlenther Onkol. 2021;197(4):269–80.
23.
Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, et al. Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev. 2016;7(7):CD003860.
24.
Dilworth JT, Griffith KA, Pierce LJ, Jagsi R, Quinn TJ, Walker EM, et al. The impact of chemotherapy on toxic effects and cosmetic outcome in patients receiving whole breast irradiation: an analysis within a statewide quality consortium. Int J Radiat Oncol Biol Phys. 2022;113(2):266–77.
25.
Purswani JM, Jaros B, Oh C, Sandigursky S, Xiao J, Gerber NK. Toxicity and cosmetic outcome of breast irradiation in women with breast cancer and autoimmune connective tissue disease: the role of fraction and field size. Pract Radiat Oncol. 2022;12(2):e90–100.
26.
Jagsi R, Griffith KA, Vicini FA, Abu-Isa E, Bergsma D, Bhatt A, et al. Disease control after hypofractionation versus conventional fractionation for triple negative breast cancer: comparative effectiveness in a large observational cohort. Int J Radiat Oncol Biol Phys. 2022;112(4):853–60.
27.
Fodor A, Brombin C, Mangili P, Borroni F, Pasetti M, Tummineri R, et al. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: should the indications for radiotherapy be more personalized?Breast. 2021;55:45–54.
28.
Vicini FA, Winter K, Freedman G, Arthur D, Hayman J, Rosenstein B, et al. Nrg RTOG 1005: a phase III trial of hypo fractionated whole breast irradiation with concurrent boost vs. Conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. Int J Radiat Oncology*Biology*Physics. 2022;114(3):S1.
29.
Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020;38(28):3261–72.
30.
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26.
31.
Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21–31.
32.
Whelan T, Levine M, Sussman J. Hypofractionated breast irradiation: what’s next?J Clin Oncol. 2020;38(28):3245–7.
33.
Strnad V, Krug D, Sedlmayer F, Piroth MD, Budach W, Baumann R, et al. DEGRO practical guideline for partial-breast irradiation. Strahlenther Onkol. 2020;196(9):749–63.
34.
Piroth MD, Strnad V, Krug D, Fastner G, Baumann R, Combs SE, et al. Long-term results of the TARGIT-A trial: more questions than answers. Breast Care. 2022;17(1):81–4.
35.
Kindts I, Laenen A, Depuydt T, Weltens C. Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev. 2017;11(11):CD011987.
36.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47–56.
37.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the eortc boost vs No boost trial: a randomized clinical trial. JAMA Oncol. 2017;3(1):42–8.
38.
Forster T, Köhler C, Dorn M, Häfner MF, Arians N, König L, et al. Noninferiority of local control and comparable toxicity of intensity modulated radiation therapy with simultaneous integrated boost in breast cancer: 5-year results of the IMRT-MC2 phase III trial. Int J Radiat Oncol Biol Phys. 2023;S0360-3016(23):00523–0.
39.
Coles CE, Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC, et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023;401(10394):2124–37.
40.
Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the national surgical adjuvant breast Project (protocol 4). Discriminants for 15-year survival. National surgical adjuvant breast and bowel Project investigators. Cancer. 1993;71(6 Suppl):2141–50.
41.
Zylka-Menhorn V. Karzinomchirurgie: ist die Lymphadenektomie nicht mehr zeitgemäß?Dtsch Arztebl. 2009;106.
42.
Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. JAMA. 2013;310(13):1385–94.
43.
Schwartz GF, Guiliano AE, Veronesi U; Consensus Conference Committee. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast April 19-22, 2001, Philadelphia, PA, USA. Breast J. 2002;8(3):124–38.
44.
Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365–83.
45.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.
46.
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32; discussion 432-3.
47.
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs No axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.
48.
Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg. 2023;110(9):1143–52.
49.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.
50.
Savolt A, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight-year follow up result of the OTOASOR trial: the Optimal Treatment of the Axilla: surgery or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672–9.
51.
Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159–65.
52.
Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, et al. AGO recommendations for the surgical therapy of breast cancer: update 2022. Geburtshilfe Frauenheilkd. 2022;82(10):1031–43.
53.
Fernandez-Gonzalez S, Falo C, Pla MJ, Pernas S, Bajen M, Soler T, et al. The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results, and the advantages and disadvantages of both procedures. Clin Breast Cancer. 2018;18(1):71–7.
54.
Banys-Paluchowski M, Untch M, Krawczyk N, Thurmann M, Kühn T, Sehouli J, et al. Current trends in diagnostic and therapeutic management of the axilla in breast cancer patients receiving neoadjuvant therapy: results of the German-wide NOGGO MONITOR 24 survey. Arch Gynecol Obstet. 2023;307(5):1547–56.
55.
Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?Ann Surg Oncol. 2018;25(6):1488–94.
56.
Banys-Paluchowski M, Rubio IT, Ditsch N, Krug D, Gentilini OD, Kühn T. Real de-escalation or escalation in disguise?Breast. 2023;69:249–57.
57.
Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, et al. Management of the axilla in early-stage breast cancer: ontario health (cancer care ontario) and ASCO guideline. J Clin Oncol. 2021;39(27):3056–82.
58.
Reimer T, Stachs A, Veselinovic K, Polata S, Müller T, Kühn T, et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2023;55:101756.
59.
Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, et al. AGO Breast Committee Recommendations: surgical therapy Update 2022. AGO Empfehlungen zur operativen Therapie des Mammakarzinoms: update 2022. GebFra. 2022.
60.
Fisher B, Montague E, Redmond C, Barton B, Borland D, Fisher ER, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6 Suppl):2827–39.
61.
Euhus DM. Management of the clinically positive axilla. Breast J. 2020;26(1):35–8.
62.
Hartmann S, Kühn T, Hauptmann M, Stickeler E, Thill M, Lux MP, et al. Axillary staging after neoadjuvant chemotherapy for initially node-positive breast carcinoma in Germany: initial data from the AXSANA study. Geburtshilfe Frauenheilkd. 2022;82(9):932–40.
63.
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.
64.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.
65.
Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343–52.
66.
Simons JM, van Nijnatten TJA, van der Pol CC, Luiten EJT, Koppert LB, Smidt ML. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269(3):432–42.
67.
Gasparri ML, de Boniface J, Poortmans P, Gentilini OD, Kaidar-Person O, Banys-Paluchowski M, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022;109(9):857–63.
68.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.
69.
Siso C, de Torres J, Esgueva-Colmenarejo A, Espinosa-Bravo M, Rus N, Cordoba O, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): a new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25(3):784–91.
70.
Hartmann S, Kühn T, de Boniface J, Stachs A, Winckelmann A, Frisell J, et al. Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial. Br J Surg. 2021;108(3):302–7.
71.
de Boniface J, Frisell J, Kühn T, Wiklander-Bråkenhielm I, Dembrower K, Nyman P, et al. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. Breast Cancer Res Treat. 2022;193(3):589–95.
72.
Renaudeau C, Gimbergues P, Guillot E, Chauvet MP, Gutowski M, Jouve M, et al. Abstract OT1-09-01: Axillary surgery de-escalation after neoadjuvant chemotherapy in breast cancer patients with initially involved node: the GANEA 3 trial. Cancer Res. 2023;83(5).
73.
Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276(5):e553–62.
74.
Hartmann S, Reimer T, Gerber B, Stubert J, Stengel B, Stachs A. Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy. Eur J Surg Oncol. 2018;44(9):1307–11.
75.
Banys-Pachulowski M, Paluchowski P, Krawczyk N. Twinkle artifact in sonographic breast clip visualization. Arch Gynecol Obstet. 2023;307(6):2021–2.
76.
Simons JM, van Nijnatten TJA, van der Pol CC, van Diest PJ, Jager A, van Klaveren D, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg. 2022;157(11):991–9.
77.
Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers. 2021;13(7):1565.
78.
Galimberti V, Ribeiro Fontana SK, Vicini E, Morigi C, Sargenti M, Corso G, et al. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients”. Breast. 2023;67:21–5.
79.
Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, et al. Central review of radiation therapy planning among patients with breast-conserving surgery: results from a quality assurance process integrated into the INSEMA trial. Int J Radiat Oncol Biol Phys. 2020;107(4):683–93.
80.
Borm KJ, Oechsner M, Düsberg M, Buschner G, Weber W, Combs SE, et al. Irradiation of regional lymph node areas in breast cancer: dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother Oncol. 2020;142:195–201.
81.
Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, et al. Radiation field design in the ACOSOG Z0011 (alliance) trial. J Clin Oncol. 2014;32(32):3600–6.
82.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201–10.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
